JP2002515267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002515267A5 JP2002515267A5 JP2000549777A JP2000549777A JP2002515267A5 JP 2002515267 A5 JP2002515267 A5 JP 2002515267A5 JP 2000549777 A JP2000549777 A JP 2000549777A JP 2000549777 A JP2000549777 A JP 2000549777A JP 2002515267 A5 JP2002515267 A5 JP 2002515267A5
- Authority
- JP
- Japan
- Prior art keywords
- pul37
- apoptotic activity
- polypeptide
- cell
- pul36
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 230000002424 anti-apoptotic effect Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 6
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 101150085237 UL36 gene Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/080,265 US6218511B1 (en) | 1998-05-18 | 1998-05-18 | Anti-apoptotic genes of human cytomegalovirus (HCMV) and their use |
| US09/080,265 | 1998-05-18 | ||
| US30112199A | 1999-04-28 | 1999-04-28 | |
| US09/301,121 | 1999-04-28 | ||
| PCT/US1999/006567 WO1999060171A1 (en) | 1998-05-18 | 1999-05-06 | Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002515267A JP2002515267A (ja) | 2002-05-28 |
| JP2002515267A5 true JP2002515267A5 (enExample) | 2006-06-15 |
Family
ID=26763295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000549777A Withdrawn JP2002515267A (ja) | 1998-05-18 | 1999-05-06 | 抗アポトーシス遺伝子及び遺伝子産物に関する化合物、スクリーニング方法並びに用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US6605426B1 (enExample) |
| EP (1) | EP1080233A4 (enExample) |
| JP (1) | JP2002515267A (enExample) |
| AU (1) | AU762756B2 (enExample) |
| CA (1) | CA2329868A1 (enExample) |
| NZ (1) | NZ507426A (enExample) |
| WO (1) | WO1999060171A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999063097A2 (en) * | 1998-06-02 | 1999-12-09 | Vertex Pharmaceuticals Incorporated | Caspase-9 deficient animals and the use thereof |
| US6465187B1 (en) * | 2000-05-08 | 2002-10-15 | Innoventus Project Ab | Method of treatment |
| EP1164374A1 (en) * | 2000-06-16 | 2001-12-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for identifying apoptosis-modified proteins |
| EP1764616B1 (en) * | 2000-06-16 | 2009-04-08 | Thomas Dr. Rudel | Method for identifying apoptosis modified proteins |
| JPWO2002052032A1 (ja) * | 2000-12-22 | 2004-04-30 | 中外製薬株式会社 | 標的細胞の細胞死の測定方法 |
| AU2003224638A1 (en) * | 2002-03-01 | 2003-09-16 | Exelixis, Inc. | PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| WO2004031144A2 (en) * | 2002-10-01 | 2004-04-15 | Musc Foundation For Research Development | Use of caspase inhibitors as therapeutic agent against radiation-induced injury |
| AU2003297281A1 (en) * | 2002-11-15 | 2004-06-15 | Chao, Wei | Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors |
| US7632972B2 (en) * | 2003-10-30 | 2009-12-15 | The Board Of Trustees Of The University Of Illionis | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells |
| KR100677114B1 (ko) * | 2004-04-27 | 2007-02-02 | 삼성전자주식회사 | 정보 저장 매체, 이 정보 저장 매체의 데이터 기록/재생방법 및 장치 |
| US7894174B2 (en) * | 2004-08-23 | 2011-02-22 | Monolithic Power Systems, Inc. | Method and apparatus for fault detection scheme for cold cathode fluorescent lamp (CCFL) integrated circuits |
| WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| AU2007253753A1 (en) | 2006-05-19 | 2007-11-29 | Board Of Trustees Of The University Of Illinois | Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers |
| US9127293B2 (en) * | 2006-07-26 | 2015-09-08 | The University Of Chicago | Receptor-mediated delivery: compositions and methods |
| WO2009042237A2 (en) * | 2007-09-26 | 2009-04-02 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| CN101453818B (zh) | 2007-11-29 | 2014-03-19 | 杭州茂力半导体技术有限公司 | 放电灯的电路保护和调节装置 |
| JP2009258579A (ja) * | 2008-03-26 | 2009-11-05 | Fujifilm Corp | 平版印刷版原版の製版方法 |
| EP2304047A4 (en) * | 2008-05-07 | 2012-12-26 | Eutropics Pharmaceuticals Inc | ANTIBODIES TAKEN UPON HETERODIMES OF THE BCL-2 FAMILY AND THEIR USES |
| EP2393794B1 (en) | 2009-02-09 | 2017-03-22 | The Board of Trustees of the University of Illionis | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| WO2011095174A1 (en) * | 2010-02-08 | 2011-08-11 | Aarhus Universitet | Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum |
| IN2014MN01780A (enExample) | 2012-02-09 | 2015-07-03 | Memed Diagnostics Ltd | |
| US20150133450A1 (en) | 2012-06-20 | 2015-05-14 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
| AU2014342269B2 (en) | 2013-10-30 | 2020-02-27 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
| CA2954601C (en) | 2014-08-14 | 2023-04-18 | Memed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
| US20170269081A1 (en) | 2014-12-11 | 2017-09-21 | Memed Diagnostics Ltd. | Marker combinations for diagnosing infections and methods of use thereof |
| CA2974240A1 (en) | 2015-01-12 | 2016-07-21 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| WO2017149548A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| IL294121B2 (en) * | 2016-03-03 | 2023-09-01 | Memed Diagnostics Ltd | An RNA test to diagnose the type of infection |
| WO2018011795A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| US11340223B2 (en) | 2016-07-10 | 2022-05-24 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| US11385241B2 (en) | 2016-09-29 | 2022-07-12 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| CN110073220A (zh) | 2016-09-29 | 2019-07-30 | 米密德诊断学有限公司 | 风险评估和疾病分类的方法 |
| KR102881208B1 (ko) * | 2019-12-18 | 2025-11-04 | 스탠다드 바이오툴즈 캐나다 인크. | 질량 세포분석 시약 및 신호 증폭 방법 |
| CN112816637A (zh) * | 2020-06-17 | 2021-05-18 | 湖南慧泽生物医药科技有限公司 | 一种吗替麦考酚酯片的体外溶出方法 |
| CN111939243B (zh) * | 2020-07-24 | 2021-04-13 | 武汉珈创生物技术股份有限公司 | Z-vad-fmk在制备人类1型单纯疱疹病毒抑制剂中的应用 |
| US20240027453A1 (en) * | 2020-07-28 | 2024-01-25 | The Trustees Of Princeton University | Method for detection and quantitative monitoring of infections with herpesviruses |
| CN111944746B (zh) * | 2020-08-04 | 2022-05-06 | 山东中医药大学 | 一种热刺激诱导细胞凋亡的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827702A (en) * | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| US5563039A (en) * | 1995-03-31 | 1996-10-08 | Tularik, Inc. | TNF receptor-associated intracellular signaling proteins and methods of use |
| US5656725A (en) * | 1995-05-12 | 1997-08-12 | Apoptosis Technology, Inc. | Peptides and compositions which modulate apoptosis |
| WO1997012632A1 (en) * | 1995-10-05 | 1997-04-10 | Tkb Associates Limited Partnership | Methods for treatment of diseases associated with a deficiency of fas ligand activity |
| JPH09124509A (ja) * | 1995-10-27 | 1997-05-13 | Sumitomo Electric Ind Ltd | 肝炎治療剤 |
| US5876923A (en) | 1996-07-26 | 1999-03-02 | Arch Development Corporation | Herpes simplex virus ICP4 as an inhibitor of apoptosis |
-
1999
- 1999-05-06 AU AU39643/99A patent/AU762756B2/en not_active Ceased
- 1999-05-06 WO PCT/US1999/006567 patent/WO1999060171A1/en not_active Ceased
- 1999-05-06 NZ NZ507426A patent/NZ507426A/en unknown
- 1999-05-06 CA CA002329868A patent/CA2329868A1/en not_active Abandoned
- 1999-05-06 EP EP99922704A patent/EP1080233A4/en not_active Withdrawn
- 1999-05-06 JP JP2000549777A patent/JP2002515267A/ja not_active Withdrawn
-
2000
- 2000-11-21 US US09/716,504 patent/US6605426B1/en not_active Expired - Fee Related
-
2003
- 2003-06-18 US US10/463,756 patent/US6902885B2/en not_active Expired - Fee Related
- 2003-06-18 US US10/463,808 patent/US20030198949A1/en not_active Abandoned
-
2005
- 2005-04-13 US US11/104,506 patent/US7449450B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002515267A5 (enExample) | ||
| Pan et al. | Isolation of virus-neutralizing RNAs from a large pool of random sequences. | |
| JP2004511201A5 (enExample) | ||
| ES2355015T3 (es) | Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. | |
| JP2005514901A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2003510366A5 (enExample) | ||
| JP2008533988A5 (enExample) | ||
| JP2002529066A5 (enExample) | ||
| JP2003503355A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2006506097A5 (enExample) | ||
| JP2006523448A5 (enExample) | ||
| JP2008521795A5 (enExample) | ||
| JP2004535161A5 (enExample) | ||
| JP2005512558A5 (enExample) | ||
| JP2004535795A5 (enExample) | ||
| JP2004537284A5 (enExample) | ||
| JP2005535289A5 (enExample) | ||
| JP2003507029A5 (enExample) | ||
| Colonno et al. | ASSESSMENT AT THREE YEARS SHOWS HIGH BARRIER TO RESISTANCE IS MAINTAINED IN ENTECAVIRTREATED NUCLEOSIDE NAïVE PATIENTS WHILE RESISTANCE EMERGENCE INCREASES OVER TIME IN LAMIVUDINE REFRACTORY PATIENTS: 110 | |
| Yurdaydin et al. | A MULTICENTER RANDOMISED STUDY COMPARING THE EFFICACY OF PEGYLATED INTERFERON-ALFA-2A PLUS ADEVOFIR DIPIVOXIL VS. PEGYLATED INTERFERON-ALFA-2A PLUS PLACEBO VS. ADEVOFIR DIPIVOXIL FOR THE TREATMENT OF CHRONIC DELTA HEPATITIS: THE HEP-NET/INTERNATIONAL DELTA HEPATITIS INTERVENTION TRIAL (HID-IT): 111 | |
| JP2008503569A5 (enExample) | ||
| JP2006501465A5 (enExample) | ||
| JP2004533848A5 (enExample) |